Curtin School of Population Health, Curtin University, Perth, WA, Australia.
Department of Health Systems and Policy, Institute of Public Health, University of Gondar, Gondar, Ethiopia.
PLoS One. 2024 Jul 2;19(7):e0306557. doi: 10.1371/journal.pone.0306557. eCollection 2024.
Despite ongoing efforts, perinatal morbidity and mortality persist across all settings, imposing a dual burden of clinical and economic strain. Besides, the fragmented nature of economic evidence on perinatal health interventions hinders the formulation of effective health policies. Our review aims to comprehensively and critically assess the economic evidence for such interventions in high-income countries, where the balance of health outcomes and fiscal prudence is paramount.
We will conduct a comprehensive search for studies using databases including EconLit (EBSCO), Cost Effectiveness Analysis (CEA) Registry, Medline (Ovid), Embase (Ovid), CINAHL Ultimate (EBSCO), Global Health (Ovid), and PubMed. Furthermore, we will broaden our search to include Google Scholar and conduct snowballing from the final articles included. The search terms will encompass economic evaluation, perinatal health interventions, morbidity and mortality, and high-income countries. We will include full economic evaluations focusing on cost-effectiveness, cost-benefit, cost-utility, and cost-minimisation analyses. We will exclude partial economic evaluations, reports, qualitative studies, conference papers, editorials, and systematic reviews. Date restrictions will limit the review to studies published after 2010 and those in English during the study selection process. We will use the modified Drummond checklist to evaluate the quality of each included study. Our findings will adhere to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) 2020 statement. A summary will include estimated costs, effectiveness, benefits, and the incremental cost-effectiveness ratio (ICER). We also plan to conduct a subgroup analysis. To aid comparability, we will standardise all costs to the United States Dollar, adjusting them to their 2022 value using country-specific consumer price index and purchasing power parity.
This systematic review will not involve human participants and requires no ethical approval. We will publish the results in a peer-reviewed journal.
We registered our record on PROSPERO (registration #: CRD42023432232).
尽管一直在努力,但围产期发病率和死亡率在所有环境中仍然存在,给临床和经济带来双重负担。此外,围产期卫生干预措施的经济证据分散,阻碍了有效的卫生政策的制定。我们的综述旨在全面、批判性地评估高收入国家此类干预措施的经济证据,在这些国家,健康结果和财政谨慎之间的平衡至关重要。
我们将使用包括 EconLit(EBSCO)、成本效果分析(CEA)登记处、Medline(Ovid)、Embase(Ovid)、CINAHL 终极版(EBSCO)、全球健康(Ovid)和 PubMed 在内的数据库,全面搜索研究。此外,我们将扩大搜索范围,包括 Google Scholar,并从最终纳入的文章进行滚雪球式搜索。搜索词将包括经济评价、围产期卫生干预措施、发病率和死亡率以及高收入国家。我们将纳入重点关注成本效益、成本效益、成本效用和成本最小化分析的全经济评价。我们将排除部分经济评价、报告、定性研究、会议论文、社论和系统评价。日期限制将使本综述仅限于 2010 年后发表的研究,以及研究选择过程中发表的英语研究。我们将使用改良的 Drummond 清单评估每项纳入研究的质量。我们的研究结果将遵循系统评价和荟萃分析的首选报告项目(PRISMA)2020 声明。总结将包括估计成本、效果、效益和增量成本效果比(ICER)。我们还计划进行亚组分析。为了便于比较,我们将所有成本标准化为美元,使用特定国家的消费者价格指数和购买力平价将其调整为 2022 年的价值。
本系统评价不涉及人类参与者,不需要伦理批准。我们将在同行评议的期刊上发表结果。
我们在 PROSPERO(注册号:CRD42023432232)上注册了我们的记录。